当前位置: 首页 >> 检索结果
共有 1921 条符合本次的查询结果, 用时 2.8026471 秒

1081. Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder.

作者: Yating Wan.;Tao Zuo.;Zhilu Xu.;Fen Zhang.;Hui Zhan.;Dorothy Chan.;Ting-Fan Leung.;Yun Kit Yeoh.;Francis K L Chan.;Ruth Chan.;Siew C Ng.
来源: Gut. 2022年71卷5期910-918页
The gut microbiota has been suggested to play a role in autism spectrum disorder (ASD). We postulate that children with ASD harbour an altered developmental profile of the gut microbiota distinct from that of typically developing (TD) children. Here, we aimed to characterise compositional and functional alterations in gut microbiome in association with age in children with ASD and to identify novel faecal bacterial markers for predicting ASD.

1082. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures.

作者: Maria Arechederra.;María Rullán.;Irene Amat.;Daniel Oyon.;Lucia Zabalza.;Maria Elizalde.;M Ujue Latasa.;Maria R Mercado.;David Ruiz-Clavijo.;Cristina Saldaña.;Ignacio Fernández-Urién.;Juan Carrascosa.;Vanesa Jusué.;David Guerrero-Setas.;Cruz Zazpe.;Iranzu González-Borja.;Bruno Sangro.;Jose M Herranz.;Ana Purroy.;Isabel Gil.;Leonard J Nelson.;Juan J Vila.;Marcin Krawczyk.;Krzysztof Zieniewicz.;Waldemar Patkowski.;Piotr Milkiewicz.;Francisco Javier Cubero.;Gorka Alkorta-Aranburu.;Maite G Fernandez-Barrena.;Jesus M Urman.;Carmen Berasain.;Matias A Avila.
来源: Gut. 2022年71卷6期1141-1151页
Despite significant progresses in imaging and pathological evaluation, early differentiation between benign and malignant biliary strictures remains challenging. Endoscopic retrograde cholangiopancreatography (ERCP) is used to investigate biliary strictures, enabling the collection of bile. We tested the diagnostic potential of next-generation sequencing (NGS) mutational analysis of bile cell-free DNA (cfDNA).

1083. Duality of the association between COVID-19 and acute pancreatitis.

作者: Xiu-He Lv.;Kai Deng.;Jin-Lin Yang.
来源: Gut. 2022年71卷1期229页

1084. COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study.

作者: Luca Saverio Belli.;Christophe Duvoux.;Paolo Angelo Cortesi.;Rita Facchetti.;Speranta Iacob.;Giovanni Perricone.;Sylvie Radenne.;Sara Conti.;Damiano Patrono.;Gabriela Berlakovich.;Angus Hann.;Luisa Pasulo.;Lluis Castells.;Francois Faitot.;Olivier Detry.;Federica Invernizzi.;Giulia Magini.;Paolo De Simone.;Ilias Kounis.;Maria Cristina Morelli.;Fernando Díaz Fontenla.;Bo-Göran Ericzon.;Carmelo Loinaz.;Chris Johnston.;Liliana Gheorghe.;Mickael Lesurtel.;Renato Romagnoli.;Dagmar Kollmann.;M Thamara Pr Perera.;Stefano Fagiuoli.;Darius Mirza.;Audrey Coilly.;Christian Toso.;Krzysztof Zieniewicz.;Laure Elkrief.;Vincent Karam.;Rene Adam.;Caroline den Hoed.;Marco Merli.;Massimo Puoti.;Luciano De Carlis.;Gabriel C Oniscu.;Salvatore Piano.;Paolo Angeli.;Constantino Fondevila.;Wojciech G Polak.; .
来源: Gut. 2021年70卷10期1914-1924页
Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course.

1085. Optimal timing of cholecystectomy after necrotising biliary pancreatitis.

作者: Nora D Hallensleben.;Hester C Timmerhuis.;Robbert A Hollemans.;Sabrina Pocornie.;Janneke van Grinsven.;Sandra van Brunschot.;Olaf J Bakker.;Rogier van der Sluijs.;Matthijs P Schwartz.;Peter van Duijvendijk.;Tessa Römkens.;Martijn W J Stommel.;Robert C Verdonk.;Marc G Besselink.;Stefan A W Bouwense.;Thomas L Bollen.;Hjalmar C van Santvoort.;Marco J Bruno.; .
来源: Gut. 2022年71卷5期974-982页
Following an episode of acute biliary pancreatitis, cholecystectomy is advised to prevent recurrent biliary events. There is limited evidence regarding the optimal timing and safety of cholecystectomy in patients with necrotising biliary pancreatitis.

1086. Sodium+/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.

作者: Ahmad Salhab.;Johnny Amer.;Yinying Lu.;Rifaat Safadi.
来源: Gut. 2022年71卷7期1373-1385页
Sodium+/ taurocholate cotransporting polypeptide (NTCP) is a membrane transporter affecting the enterohepatic circulation of bile acids (BAs). We aimed to evaluate NTCP's roles in humans and animal models of liver fibrosis (LF).

1087. Automated sizing of colorectal polyps using computer vision.

作者: Mohamed Abdelrahim.;Hiroyasu Saiga.;Naoto Maeda.;Ejaz Hossain.;Hitoshi Ikeda.;Pradeep Bhandari.
来源: Gut. 2022年71卷1期7-9页

1088. Recent advances in clinical practice: epidemiology of autoimmune liver diseases.

作者: Palak J Trivedi.;Gideon M Hirschfield.
来源: Gut. 2021年70卷10期1989-2003页
Autoimmune liver diseases are chronic inflammatory hepatobiliary disorders that when classically defined encompass three distinctive clinical presentations; primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). Meaningful changes in disease epidemiology are reported, with increasing incidence and prevalence of AIH and PSC in Europe, and rising prevalence of PBC across Europe, North America and the Asia-Pacific region. However, there appears to be very significant global variation with contemporary incidence rates of disease per 100 000 ranging from 0.84 to 2.75 for PBC, 0.1 to 4.39 for PSC and 0.4 to 2.39 for AIH. Prevalence corresponds, and per 100 000 estimates for PBC range from 1.91 to 40.2, for PSC between 0.78 and 31.7 and for AIH from 4.8 to 42.9. Population-based studies and multicentre observational cohort series provide improved understanding of the clinical course that patients experience, highlighting variations in presenting phenotypes geographically and temporally. Collectively, while autoimmune liver diseases are rare, the clinical burden is disproportionately high relative to population incidence and prevalence. Age, sex and race also impact clinical outcomes, and patient morbidity and mortality are reflected by high need for gastroenterology, hepatology and organ transplant services.

1089. Proton pump inhibitors and gastric cancer: a population-based cohort study.

作者: Jigar Patel.;Ivan Berezowski.;Rajesh Naidu Janapala.;Ali Pourmand.
来源: Gut. 2022年71卷5期1039-1041页

1090. Incorrectly analysing stratified and minimised trials may lead to wrongfully rejecting superiority of interventions.

作者: Reinier Cornelis Anthonius van Linschoten.;Rachel West.;Desirée van Noord.;Nikki van Leeuwen.
来源: Gut. 2022年71卷5期1038-1039页

1091. Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response.

作者: Shanshan Xiong.;Charles E Whitehurst.;Li Li.;Gyu Seong Heo.;Chin-Wen Lai.;Umang Jain.;Brian D Muegge.;Scott T Espenschied.;Ryan J Musich.;Minhu Chen.;Yongjian Liu.;Ta-Chiang Liu.;Thaddeus S Stappenbeck.
来源: Gut. 2022年71卷7期1289-1301页
Fibrosis is a common feature of Crohn's disease (CD) which can involve the mesenteric fat. However, the molecular signature of this process remains unclear. Our goal was to define the transcriptional signature of mesenteric fibrosis in CD subjects and to model mesenteric fibrosis in mice to improve our understanding of CD pathogenesis.

1092. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.

作者: Paul Oster.;Laurie Vaillant.;Erika Riva.;Brynn McMillan.;Christina Begka.;Caroline Truntzer.;Corentin Richard.;Marine M Leblond.;Meriem Messaoudene.;Elisavet Machremi.;Emeric Limagne.;Francois Ghiringhelli.;Bertrand Routy.;Gregory Verdeil.;Dominique Velin.
来源: Gut. 2022年71卷3期457-466页
In this study, we determined whether Helicobacter pylori (H. pylori) infection dampens the efficacy of cancer immunotherapies.

1093. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.

作者: Jianpeng Sheng.;Junlei Zhang.;Lin Wang.;Vincent Tano.;Jianghui Tang.;Xun Wang.;Jiangchao Wu.;Jinyuan Song.;Yaxing Zhao.;Jingxia Rong.;Fei Cheng.;Jianfeng Wang.;Yinan Shen.;Liang Wen.;Junjun He.;Hui Zhang.;Taohong Li.;Qi Zhang.;Xueli Bai.;Zhimin Lu.;Tingbo Liang.
来源: Gut. 2022年71卷6期1176-1191页
Hepatocellular carcinoma (HCC) tumour microenvironment (TME) is highly complex with diverse cellular components organising into various functional units, cellular neighbourhoods (CNs). And we wanted to define CN of HCC while preserving the TME architecture, based on which, potential targets for novel immunotherapy could be identified.

1094. Hidden link in gut-joint axis: gut microbes promote rheumatoid arthritis at early stage by enhancing ascorbate degradation.

作者: Yan Zhao.;Mingyue Cheng.;Liang Zou.;Luxu Yin.;Chaofang Zhong.;Yuguo Zha.;Xue Zhu.;Lei Zhang.;Kang Ning.;Jinxiang Han.
来源: Gut. 2022年71卷5期1041-1043页

1095. Rapid resolution of COVID-19 after faecal microbiota transplantation.

作者: Jarosław Biliński.;Katarzyna Winter.;Marcin Jasiński.;Anna Szczęś.;Natalia Bilinska.;Benjamin H Mullish.;Ewa Małecka-Panas.;Grzegorz W Basak.
来源: Gut. 2022年71卷1期230-232页

1096. Braf mutation induces rapid neoplastic transformation in the aged and aberrantly methylated intestinal epithelium.

作者: Lochlan Fennell.;Alexandra Kane.;Cheng Liu.;Diane McKeone.;Gunter Hartel.;Chang Su.;Catherine Bond.;Mark Bettington.;Barbara Leggett.;Vicki Whitehall.
来源: Gut. 2022年71卷6期1127-1140页
Sessile serrated lesions (SSLs) are common across the age spectrum, but the BRAF mutant cancers arising occur predominantly in the elderly. Aberrant DNA methylation is uncommon in SSL from young patients. Here, we interrogate the role of ageing and DNA methylation in SSL initiation and progression.

1097. Proton pump inhibitors and risk of gastric cancer: population-based cohort study.

作者: Devin Abrahami.;Emily Gibson McDonald.;Mireille E Schnitzer.;Alan N Barkun.;Samy Suissa.;Laurent Azoulay.
来源: Gut. 2022年71卷1期16-24页
To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs).

1098. Proton pump inhibitors and risk of colorectal cancer.

作者: Devin Abrahami.;Emily Gibson McDonald.;Mireille E Schnitzer.;Alan N Barkun.;Samy Suissa.;Laurent Azoulay.
来源: Gut. 2022年71卷1期111-118页
To determine whether proton pump inhibitors (PPIs) are associated with an increased risk of colorectal cancer, compared with histamine-2 receptor antagonists (H2RAs).

1099. Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis.

作者: Jue-Sheng Ong.;Jiyuan An.;Xikun Han.;Matthew H Law.;Priyanka Nandakumar.; .; .;Johannes Schumacher.;Ines Gockel.;Anne Bohmer.;Janusz Jankowski.;Claire Palles.;Catherine M Olsen.;Rachel E Neale.;Rebecca Fitzgerald.;Aaron P Thrift.;Thomas L Vaughan.;Matthew F Buas.;David A Hinds.;Puya Gharahkhani.;Bradley J Kendall.;Stuart MacGregor.
来源: Gut. 2022年71卷6期1053-1061页
Gastro-oesophageal reflux disease (GERD) has heterogeneous aetiology primarily attributable to its symptom-based definitions. GERD genome-wide association studies (GWASs) have shown strong genetic overlaps with established risk factors such as obesity and depression. We hypothesised that the shared genetic architecture between GERD and these risk factors can be leveraged to (1) identify new GERD and Barrett's oesophagus (BE) risk loci and (2) explore potentially heterogeneous pathways leading to GERD and oesophageal complications.

1100. Artificial intelligence and colonoscopy experience: lessons from two randomised trials.

作者: Alessandro Repici.;Marco Spadaccini.;Giulio Antonelli.;Loredana Correale.;Roberta Maselli.;Piera Alessia Galtieri.;Gaia Pellegatta.;Antonio Capogreco.;Sebastian Manuel Milluzzo.;Gianluca Lollo.;Dhanai Di Paolo.;Matteo Badalamenti.;Elisa Ferrara.;Alessandro Fugazza.;Silvia Carrara.;Andrea Anderloni.;Emanuele Rondonotti.;Arnaldo Amato.;Andrea De Gottardi.;Cristiano Spada.;Franco Radaelli.;Victor Savevski.;Michael B Wallace.;Prateek Sharma.;Thomas Rösch.;Cesare Hassan.
来源: Gut. 2022年71卷4期757-765页
Artificial intelligence has been shown to increase adenoma detection rate (ADR) as the main surrogate outcome parameter of colonoscopy quality. To which extent this effect may be related to physician experience is not known. We performed a randomised trial with colonoscopists in their qualification period (AID-2) and compared these data with a previously published randomised trial in expert endoscopists (AID-1).
共有 1921 条符合本次的查询结果, 用时 2.8026471 秒